Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: Outcome and associated factors

Dana Livne-Segev, Maya Gottfried, Natalie Maimon, Avivit Peer, Avivit Neumann, Henry Hayat, Svetlana Kovel, Avishay Sella, Wilmosh Mermershtain, Keren Rouvinov, Ben Boursi, Rony Weitzen, Raanan Berger, Daniel Keizman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The VEGFR/PDGFR inhibitor sunitinib was approved in Israel in 2008 for the treatment of metastatic renal cell carcinoma (mRCC), based on an international trial. However, the efficacy of sunitinib treatment in Israeli mRCC patients has not been previously reported. Objectives: To report the outcome and associated factors of sunitinib treatment in a large cohort of Israeli mRCC patients. Methods: We conducted a retrospective study of an unselected cohort of mRCC patients who were treated with sunitinib during the period 2006-2013 in six Israeli hospitals. Univariate and multivariate analyses were performed to determine the association between treatment outcome and clinicopathologic factors. Results: We identified 145 patients; the median age was 65 years, 63% were male, 80% had a nephrectomy, and 28% had prior systemic treatment. Seventy-nine percent (n=115) had clinical benefit (complete response 5%, n=7; partial response 33%, n= 48; stable disease 41%, n=60); 21% (n=30) were refractory to treatment. Median progression-free survival (PFS) was 12 months and median overall survival 21 months. Factors associated with clinical benefit were sunitinib-induced hypertension: [odds ratio (OR) 3.6, P = 0.042] and sunitinib dose reduction or treatment interruption (OR 2.4, P = 0.049). Factors associated with PFS were female gender [hazard ratio (HR) 2, P = 0.004], pre-sunitinib treatment neutrophil-to-lymphocyte ratio ≤ 3 (HR 2.19, P = 0.002), and active smoking (HR 0.19, P < 0.0001). Factors associated with overall survival were active smoking (HR 0.25, P < 0.0001) and sunitinib-induced hypertension (HR 0.48, P = 0.005). To minimize toxicity, the dose was reduced or the treatment interrupted in 39% (n=57). Conclusions: The efficacy of sunitinib treatment for mRCC among Israeli patients is similar to that in international data.

Original languageEnglish
Pages (from-to)347-351
Number of pages5
JournalIsrael Medical Association Journal
Volume16
Issue number6
StatePublished - Jun 2014
Externally publishedYes

Keywords

  • Metastatic renal cell carcinoma (mRCC)
  • Overall survival (OS)
  • Progression-free survivall (PFS)
  • Sunitinib

Fingerprint

Dive into the research topics of 'Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: Outcome and associated factors'. Together they form a unique fingerprint.

Cite this